CEO & Co-Founder of Glint Lab | Passionate About Ethical AI, Lab Automation, and Digital Pathology
Recently, my perspective has shifted, AI tools have become so intuitive that doctors don’t need to be tech experts anymore. They can focus on their specialty while getting a boost from their silicon-based assistant. It’s amazing how intuitive these tools are becoming! Take Modella AI’s #digitalpathology decision support software, for example. With its ChatGPT-style interface, it feels familiar and easy to use, making AI a natural part of the workflow. I’m curious how pathologists feel about integrating tools like this into their workflow. At the end of the day, #adoption always speaks louder than #opinions. Let’s see how it plays out!
🎉✨We are excited to report that PathChat™ DX, our clinical-grade, generative AI co-pilot for pathology, has officially received Breakthrough Device Designation from the FDA! This marks a pivotal step forward in our quest to transform biomedicine with generative and agentic AI.🌟🚀 📖 Read our press release: https://lnkd.in/e9rymEC6 🎥 See our latest demo for PathChat™ 2a below 👇 📄 Read the PathChat™ article in Nature: https://lnkd.in/ea8SmfgV We’re excited to continue pushing the boundaries of innovation in healthcare! #DigitalPathology #ComputationalPathology #AI4Pathology #pathology #ai
Improving patient outcomes
1moSeems as if that would be the case, but when you need to sign your name (license) to the bottom of a pathology report, it’s a different mindset. By continuing to improve AI’s precision and accuracy, and educating the market as to how the conclusions came about, we’ll begin to soften resistance and accelerate adoption. Will take time, but the Dx quality gains will overcome resistance.